| A further inquiry into the pollution haven hypothesis and the environmental Kuznets curve A Kearsley, M Riddel Ecological Economics 69 (4), 905-919, 2010 | 427 | 2010 |
| Physician understanding and willingness to prescribe biosimilars: findings from a US national survey AR Kolbe, A Kearsley, L Merchant, E Temkin, A Patel, J Xu, A Jessup BioDrugs 35, 363-372, 2021 | 27 | 2021 |
| The Challenge of Foreclosed Properties: An Analysis of State and Local Plans to use the Neighborhood Stabilization Program A Sheldon, P Bush, A Kearsley, A Gass Enterprise Community Partners Inc, 2009 | 9 | 2009 |
| Willingness to pay to standardize patient medication information BC Dealy, A Kearsley, C Wolff, E Botkins, N Lew, C Nardinelli Applied Economics 53 (9), 1112-1126, 2021 | 1 | 2021 |
| FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time KL Miller, AD Stern, A Kearsley, J Kao Health Affairs 43 (7), 1003-1010, 2024 | | 2024 |
| Benefit–Cost Analysis of the HHS COVID-19 Campaign: April 2021–March 2022 S Turner, EC Kranzler, S Trigger, A Kearsley, JN Luchman, CJ Williams, ... American Journal of Preventive Medicine, 2024 | | 2024 |
| A survey on perceived medication guide reading and comprehension ease among US adults PR Jones, J Santiago, BM Pearsall, DM Chu, C Wolff, A Kearsley Health Promotion International 39 (1), daad190, 2024 | | 2024 |
| Measuring the Willingness-to-pay for standardizing medication information: a two-pronged stated preference approach BC Dealy, C Wolff, A Kearsley, E Botkins Applied Economics, 1-19, 2023 | | 2023 |
| A Retrospective and Commentary on FDA’s Bar Code Rule A Kearsley, N Lew, C Nardinelli Journal of Benefit-Cost Analysis 9 (3), 496-518, 2018 | | 2018 |
